Auris Medical to Develop KRAS-Targeting RNA Treatment for

• Remedy of KRAS-pushed colorectal cancer chosen as to start with therapeutic indicator for OligoPhore™ platform
• Business to start progress software under venture code AM-401 with intention of IND submission in late 2022

Hamilton, Bermuda, July 6, 2021 – Auris Health-related Holding Ltd. (NASDAQ: EARS), a company focused to addressing unmet medical requirements via RNA therapeutics, allergy and viral infection safety, and internal ear therapeutics, currently declared the selection of mutant KRAS-pushed colorectal most cancers as the initial therapeutic indicator for its OligoPhore™ oligonucleotide shipping and delivery platform. The Corporation intends to produce the treatment below undertaking code AM-401 with submission of an IND targeted for the stop of 2022.

Addressing large unmet medical will need

Colorectal most cancers (CRC) is the fourth most commonly identified cancer and the second top cause of cancer demise in the US.¹ In 2021, there will be an believed 149,500 new cases of CRC in the US, and 52,980 fatalities from CRC.² Around 40 to 50% of sufferers with CRC harbor mutations of the KRAS gene,³ which are recognized to contribute to the enhancement, invasion and metastasis of CRC. KRAS encodes the Ras protein which controls – like an “on / off switch” – cell development, cell maturation, and cell dying. By way of the mutations, the Ras proteins can be rendered persistently lively, producing most cancers cells to develop and spread in the human body.

Beside CRC, KRAS mutations are often noticed in pancreatic most cancers and lung most cancers. Roughly 19% of patients with cancer harbor Ras mutations, equal to close to 3.4 million new cases per 12 months around the globe.⁴ Mutations in KRAS by itself account for about 1 million deaths for every yr globally.⁵ Even though the purpose of KRAS mutations in most cancers has been recognised for many years, they have remained a hard concentrate on for therapeutic interventions. Only not long ago two little molecule inhibitors of one KRAS mutations were authorized in a breakthrough by the Food stuff and Drug Administration (Food and drug administration) for use in the remedy of non-small mobile lung cancer (NSCLC).

Compelling final results in KRAS-driven versions of colorectal and pancreatic most cancers

The variety of CRC as the to start with therapeutic sign for the OligoPhore™ know-how was built centered on the high unmet healthcare want, powerful results from studies with OligoPhore™ enabled KRAS silencing, and a effectively-outlined regulatory and advancement pathway. In vitro and in vivo experiments performed jointly by investigate groups from Washington University, St. Louis MO and the University of South Florida, Tampa FL, demonstrated successful uptake of OligoPhore™ nanoparticles with KRAS-qualified siRNA in colorectal and pancreatic most cancers cells, sturdy inhibition of KRAS expression, diminished viability of tumor cells and important reduction in tumor progress and quantity.⁶ Importantly, a murine model shown the capacity of the OligoPhore™ system to generate focused shipping and delivery of the nanoparticles exclusively to tumor cells.

“In our preclinical studies with OligoPhore enabled siRNA supply, we have shown potent knock down of KRAS in a hugely qualified and efficient vogue, which inhibited a critical driver of cancer cell proliferation and metastases”, commented Samuel Wickline, MD, Auris Medical’s Chief Scientific Officer. “Based on these powerful info and the outcomes from our in depth critique of strategic growth possibilities, we search forward to advancing OligoPhore very first in colorectal cancer in advance of applying the engineering also to other therapeutic indications. Thanks to its adaptability and specificity, OligoPhore can be made use of to at the same time produce diverse siRNA payloads for broad concentrate on inhibition, which opens exciting novel therapeutic options.”

About OligoPhore™

OligoPhore™ is a flexible system for risk-free and effective supply of oligonucleotides these kinds of as siRNA (smaller interfering ribonucleic acid) into goal cells, working with systemic or neighborhood administration. It is based on a proprietary 21 amino acid peptide that can interact any style of RNA, which include mRNA, in swift self-assembly into a polyplex. The polyplex has a dimension, cost, and other actual physical capabilities that make it possible for it to escape hepatic clearance and thus to attain other goal tissues than the liver. OligoPhore™ guards the RNA payload from degradation in the circulation and allows for speedy mobile uptake, while enabling pH-dependent nucleotide complete endosomal escape and cytoplasmic delivery. Effective delivery and beneficial cure outcomes have been shown in extra than 10 diverse murine types of sickness for most cancers, cardiovascular, and rheumatological targets in the NF-κB spouse and children, various customers of the ETS transcription component relatives, and targets in the JNK and TAM pathways.

About Auris Medical

Auris Health care is committed to acquiring therapeutics that deal with crucial unmet health care requirements. The Organization is at this time active in three spots: the progress of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms preclinical), nasal sprays for safety towards airborne viruses and allergens (Bentrio™ pre-business) or the remedy of vertigo (AM-125 Phase 2), and the advancement of therapeutics for intratympanic remedy of tinnitus or hearing decline (Keyzilen® and Sonsuvi®, Stage 3). The Corporation was founded in 2003 and is headquartered in Hamilton, Bermuda with its primary functions in Basel, Switzerland. The shares of Auris Health-related Keeping Ltd. trade on the NASDAQ Cash Marketplace underneath the symbol “EARS.” The Business will change its title to “Altamira Therapeutics Ltd.” and its ticker symbol to “CYTO”, subject matter to approval by a Exclusive Common Meeting of shareholders to be held on July 21, 2021.

Ahead-looking Statements

This press release may well contain statements that constitute “forward-seeking statements” in just the which means of Portion 27A of the Securities Act of 1933 and Area 21E of the Securities Trade Act of 1934. Ahead-looking statements are statements other than historical info and may perhaps contain statements that tackle long term operating, economic or enterprise functionality or Auris Medical’s tactics or expectations. In some situations, you can recognize these statements by forward-searching terms this kind of as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the destructive of these terms or other comparable terminology. Forward-searching statements are based on management’s present-day expectations and beliefs and involve significant hazards and uncertainties that could induce actual success, developments and small business choices to differ materially from people contemplated by these statements. These hazards and uncertainties incorporate, but are not confined to, the acceptance and timing of commercialization of AM-301, Auris Medical’s will need for and skill to elevate considerable additional funding to continue the growth of its solution candidates, the timing and carry out of clinical trials of Auris Medical’s product or service candidates, the medical utility of Auris Medical’s products candidates, the timing or chance of regulatory filings and approvals, Auris Medical’s mental property place and Auris Medical’s economical position, which include the impression of any future acquisitions, inclinations, partnerships, license transactions or variations to Auris Medical’s funds construction, like upcoming securities offerings. These dangers and uncertainties also include, but are not constrained to, those described under the caption “Risk Factors” in Auris Medical’s Annual Report on Kind 20-F for the year ended December 31, 2020, and in Auris Medical’s other filings with the SEC, which are readily available no cost of cost on the Securities Trade Commission’s web page at: www.sec.gov. Must one or extra of these challenges or uncertainties materialize, or should fundamental assumptions verify incorrect, genuine effects may possibly differ materially from those people indicated. All forward-searching statements and all subsequent prepared and oral ahead-wanting statements attributable to Auris Medical or to folks acting on behalf of Auris Healthcare are expressly certified in their entirety by reference to these hazards and uncertainties. You really should not area undue reliance on ahead-hunting statements. Forward-wanting statements converse only as of the date they are made, and Auris Health care does not undertake any obligation to update them in mild of new data, potential developments or in any other case, apart from as could be required below relevant law.

Investor make contact with:

[email protected]

---

1 Benson AB et al. (2021), NCCN clinical follow tips in oncology, colon cancer, variation 2.2021, JNCCN 19(3):329-59.
2 National Cancer Institute, https://seer.cancer.gov/statfacts/html/colorect.html
3 Armstrong SA et al. (2020), Molecular profiling in metastatic colorectal most cancers, Oncology (Williston Park) 34(9):352-5.
4 Prior IA et al. (2020), The frequency of Ras mutations in cancer, Most cancers Res 80(14):2969-74.
5 Simanshu DK et al. (2017), RAS proteins and their regulators in human sickness, Cell 170(1):17-33.

6 Strand MS et al. (2019), Precision Shipping of RAS-inhibiting siRNA to KRAS driven most cancers by using peptide-primarily based nanoparticles, OncoTarget 10(46):4761-75.